CAMBRIDGE, England--(BUSINESS WIRE)--Sep 10, 2018--F-star, a biopharmaceutical company developing novel bispecific antibodies, today announces the appointment of Nessan Bermingham, Ph.D. as Chairman of its Board of Directors. Nessan succeeds John Edwards who has been F-star’s Chairman for seven years and will remain as a non-executive director.

Dr Nessan Bermingham is a highly qualified healthcare entrepreneur, with an impressive track record of building, growing and consolidating both private and public biotech companies. Based in Boston, USA, he has over a decade of experience in the life science industry, venture capital, secondary and public markets. Most recently, Nessan co-founded Intellia Therapeutics, a company developing potentially curative genome editing treatments for people living with severe and life-threatening diseases, and led it to a successful listing on NASDAQ (NASDAQ:NTLA).

John Haurum, CEO of F-star said “ On behalf of the Board, I would like to thank John Edwards for his remarkable seven-year tenure as our Chairman and we look forward to his continuing contribution to F-star’s success. Nessan Bermingham brings a huge amount of experience, complementing the skills and expertise that we already have and I am confident he will play a vital role in supporting the next stage of our corporate development, helping us achieving our ambition to become a key player in the immuno-oncology space.”

Commenting on his appointment Nessan Bermingham, Chairman of F-star said “It is an exciting time to be joining F-star’s Board. The Company is widely recognised as a leader in the bispecific antibody space and I am thrilled by the opportunities and prospects ahead of us. I am looking forward to supporting F-star in its mission to develop first-in-class therapies that have the potential to become life-changing treatments for cancer patients.”

- ENDS –

About F-star

F-star is a clinical-stage biopharmaceutical company committed to delivering life-changing treatments to cancer patients. Through our highly efficient Modular Antibody Technology™ platform, we are building and progressing an extensive immuno-oncology pipeline of mAb²™, a novel class of disruptive bispecific antibodies designed to unlock new biology which cannot be achieved by combining monospecific drugs. F-star’s technological expertise and scientific approach have been validated through strategic partnerships with leaders in the pharma and biotech industries.

Find out more at Connect with us via LinkedIn and Twitter.

View source version on


Pierre Peotta

Communications Manager

+44 (0)1223 948 094

+44 (0)7392 080 279


Instinctif Partners (UK and RoW)

Sue Charles/Ashley Tapp

+44 (0)20 7866 7923


Lazar Partners (USA)

Glenn Silver

+1 212 867 1762



SOURCE: F-star

Copyright Business Wire 2018.

PUB: 09/10/2018 07:00 AM/DISC: 09/10/2018 07:01 AM